- Alcohol | Coffee | Lack of Sleep: Which will increase the onset of arrhythmia?
- Milestone: CLIP1-LTK as New Target of Non-Small Cell Lung Cancer
- Geriatric Oncology Breakthrough: Reduce toxic side effects by 20%
- Why human ability to heal after injury becomes worse and worse?
- Study confirmed the causal relationship between vitamin D deficiency and death
- Different time of immunotherapy medication may cause the death risk double
Half-year effectiveness: Moderna COVID-19 vaccine is higher than Pfizer’s
- Israel new drug for COVID-19: EXO-CD24 can reduce deaths by 50%
- COVID-19 vaccines for children under 12 will be available soon
- Breakthrough infection of Delta: No difference from regular COVID-19 cases
- French research: ADE occurred in Delta variant and many doubts on it
- The viral load of Delta variant is 1260 times the original COVID-19 strain
Half-year effectiveness: Moderna COVID-19 vaccine is higher than Pfizer’s, or booster shot before winter.
The effectiveness of Moderna’s COVID-19 vaccine is still as high as 93% 4 to 6 months after the second vaccination, which is almost indistinguishable from the 94% effectiveness reported in the initial clinical trial.
Moderna said in its financial report on Thursday that the effectiveness of its COVID-19 mRNA vaccine is still as high as 93% 4 to 6 months after the second vaccination, which is almost indistinguishable from the 94% effectiveness reported in the initial clinical trial. The data is higher than the effectiveness data of Pfizer and BioNTech vaccine 6 months after the second dose.
According to data released by Pfizer last week, the effectiveness of the COVID-19 vaccine developed by the company and Byentec drops by an average of about 6% every two months, and it drops to about 84% 6 months after the second dose. Both Pfizer and Moderna’s vaccines use the mRNA technology route, and the effectiveness data reported in the initial clinical trials are almost the same.
Moderna announced its second-quarter results before the market on August 5, showing sales of 4.4 billion U.S. dollars, net income of 2.78 billion U.S. dollars, and earnings per share of 6.46 U.S. dollars, all exceeding expectations.
Moderna’s share price has risen by nearly 80% in the past month, and has risen by more than 300% this year, and its current market value has exceeded 160 billion US dollars. “Moderna has created the history of the biotechnology industry. No biotechnology company can achieve such growth in such a short period of time.” The reporter said.
Moderna also stated that it is conducting Phase II clinical trials of booster vaccines against three different new coronavirus variants, including the first discovered Gamma, Beta and Delta variants in Brazil, South Africa and India. The three different booster vaccine studies are all A strong antibody response against important mutations was induced, and the enhanced neutralizing antibody level was close to the antibody level observed after the second vaccination. This data has been submitted to a peer-reviewed journal for publication.
“We think that a third booster vaccine may be needed before winter.” Moderna said. At present, the US drug regulatory agency has not approved the booster vaccination, but drugmakers including Pfizer have stated in recent months that it is expected that people will eventually need booster vaccination and that additional doses will be needed every year, just like seasonal flu. Same.
At present, various countries are debating whether to vaccinate the booster vaccine. In response, Jin Dongyan, a professor at the School of Biomedical Sciences at the Li Ka-shing School of Medicine of the University of Hong Kong, said in an interview with the media: “The mutation of the new coronavirus is still slower than that of seasonal influenza viruses. The vaccine is of course the best, but now many people in academia and industry believe that the existing vaccine can still be effective against the Delta variant, and there is no need for an updated version of the vaccine for the time being.”
Jin Dongyan believes that, technically speaking, upgrading the vaccine against the Delta mutant strain can be achieved, and it will not take too long.
This year, Moderna has signed a vaccine order worth 20 billion U.S. dollars. The company is expected to be able to produce 800 million to 1 billion doses of vaccine, and next year’s vaccine production capacity will reach 2 billion to 3 billion doses. The company is submitting a full approval application for the COVID-19 vaccine to the U.S. Food and Drug Administration, and it is expected to complete the submission in August.
But in terms of production scale, Pfizer is still higher than Moderna. Pfizer expects to produce as many as 3 billion doses of vaccine this year, and raises its sales forecast for the COVID-19 vaccine to $33.5 billion this year.
(source:internet, reference only)